



Methadone Test Strip (Urine)

*A rapid, one step test for the qualitative detection of Methadone in human urine.
For in vitro diagnostic use only.*

INTENDED USE

The MTD One Step Methadone Test Strip (Urine) is a lateral flow chromatographic immunoassay for the detection of Methadone in human urine at a cut-off concentration of 300ng/mL.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

SUMMARY

Methadone is a narcotic pain reliever for medium to severe pain. It is also used in the treatment of Heroin (Opiate dependence: Vicodin, Percocet, Morphine, ect) addiction. Oral Methadone is very different than the IV Methadone. Oral Methadone is partially stored in the liver for later use. IV Methadone acts more like Heroin. In most states you must go to a pain clinic or a Methadone maintenance clinic to be prescribed Methadone.

Methadone is a long acting pain reliever producing effects that last between twelve to forty-eight hours. Ideally, Methadone frees the client from the pressures of obtaining illegal Heroin, from the dangers of injection, and from the emotional roller coaster that most Opiates produce. Methadone if taken for long periods and at large doses can lead to a very long withdrawal period. The withdrawals from Methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.¹

The MTD One Step Methadone Test Strip (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Methadone in urine. The MTD One Step Methadone Test Strip (Urine) yields a positive result when the Methadone in urine exceeds 300 ng/mL.

PRINCIPLE

The MTD One Step Methadone Test Strip (Urine) is an

immunoassay based on the principle of competitive binding. Drugs that may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a urine specimen migrates upward by capillary action. Methadone, if present in the urine specimen below 300 ng/mL, will not saturate the binding sites of antibody-coated particles in the test. The antibody coated particles will then be captured by immobilized Methadone-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Methadone level exceeds 300 ng/mL because it will saturate all the binding sites of anti-Methadone antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test Strip contains mouse anti-Methadone antibody coupled particles and Methadone-protein conjugate. A goat antibody is employed in the control line system.

PRECAUTIONS

- For *in vitro* diagnostic use only. Do not use after the expiration date.
- The test Strip should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test Strip should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test Strip is stable through the expiration date printed on the sealed pouch. The test Strip must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear supernatant for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to assay. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be

thawed and mixed before testing.

MATERIALS

Materials Provided

- Test strips
- Package insert


Materials Required But Not Provided

- Specimen collection container
- Timer

DIRECTIONS FOR USE

Allow the test strip, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.

1. Bring the pouch to room temperature before opening it. Remove the test strip from the sealed pouch and use it as soon as possible.
2. With arrows pointing toward the urine specimen, **immerse the test strip vertically in the urine specimen for at least 10-15 seconds.** Do not pass the maximum line (MAX) on the test strip when immersing the strip. See the illustration below.



Place the test strip on a non-absorbent flat surface, start the timer and wait for the red line(s) to appear. The result should be read at 5 minutes. Do not interpret the result after 10 minutes. INTERPRETATION OF RESULTS

(Please refer to the illustration above)

NEGATIVE: * Two lines appear. One red line should be in the control region (C), and another apparent red or pink line should be in the test region (T). This negative result indicates that the Methadone concentration is below the detectable cut-off level (300 ng/mL).

***NOTE:** The shade of red in the test line region (T) may vary, but it should be considered negative whenever there is even a faint pink line.

POSITIVE: One red line appears in the control region (C). No line appears in the test region (T). This positive result indicates that the Methadone concentration exceeds

the detectable cut-off level (300 ng/mL).

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test Strip. If the problem persists, discontinue using the lot immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper test performance.

LIMITATION

1. The MTD One Step Methadone Test Strip (Urine) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.^{2,3}
2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
4. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in urine.
5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
6. Test does not distinguish between drugs of abuse and certain medications.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the MTD One Step Methadone Test Strip (Urine) and a leading commercially available MTD rapid test. Testing was performed on specimens previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS. The following results were tabulated:

Method	Other MTD Rapid Test	MTD Rapid Test		Total Results
		Positive	Negative	
Atlas One Step	Results	Positive	Negative	132
	Positive	132	0	

Test Strip	Negative	0	168	168
Total Results		132	168	300
% Agreement with this Rapid Test Kit		>99%	>99%	>99%

When compared to GC/MS at the cut-off of 300 ng/mL, the following results were tabulated:

Method	Results	GC/MS		Total Results
		Positive	Negative	
Atlas One Step Test Strip	Positive	122	10	132
	Negative	1	167	168
Total Results		123	177	300
% Agreement with GC/MS Analysis		99%	94%	96%

Analytical Sensitivity

A drug-free urine pool was spiked with Methadone at the following concentrations: 0 ng/mL, 150 ng/mL, 225 ng/mL, 300 ng/mL, 375 ng/mL and 450 ng/mL. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized below:

MTD Concentration (ng/mL)	Percent of Cut-off	n	Visual Result	
			Negative	Positive
0	0	30	30	0
150	-50%	30	30	0
225	-25%	30	26	4
300	Cut-off	30	16	14
375	+25%	30	4	26
450	+50%	30	0	30

Analytical Specificity

The following table lists compounds that are positively detected in urine by the MTD One Step Methadone Test Strip (Urine) at 5 minutes.

Compound	Concentration (ng/mL)
Methadone	300
Doxylamine	50,000

Precision

A study was conducted at 3 physician's offices by untrained operators using 3 different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens containing no Methadone, 25% Methadone above and below the cut-off and 50% Methadone above and below the 300 ng/mL cut-off was provided to each site. The following results were tabulated:

Methadone conc. (ng/mL)	n per site	Site A		Site B		Site C	
		-	+	-	+	-	+
0	15	15	0	15	0	15	0
150	15	10	5	13	2	14	1
225	15	4	11	13	2	13	2
375	15	0	15	1	14	0	15
450	15	0	15	0	15	0	15

Effect of Urinary Specific Gravity

Fifteen (15) urine samples with specific gravity ranging from 1.001 to 1.032 were spiked with 150 ng/mL and 450 ng/mL of Methadone respectively. The MTD One Step Methadone Test Strip (Urine) was tested in duplicate using the fifteen neat and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of the Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with Methadone to 150 ng/ml and 450 ng/ml. The spiked, pH-adjusted urine was tested with the MTD One Step Methadone Test Strip (Urine) in duplicate. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or Methadone positive urine. The following compounds show no cross-reactivity when tested with the MTD One Step Methadone Test Strip (Urine) at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds

Acetaminophen	Estrone-3-sulfate	Oxymetazoline
Acetophenetidin	Ethyl-p-aminobenzoate	Papaverine
N-	Fenoprofen	Penicillin-G
Acetylprocainamide		
Acetylsalicylic acid	Furosemide	Pentazocine hydrochloride
Aminopyrine	Gentisic acid	Pentobarbital
Amitypyline	Hemoglobin	Perphenazine
Amobarbital	Hydralazine	Phencyclidine
Amoxicillin	Hydrochlorothiazide	Phenelzine
Ampicillin	Hydrocodone	Phenobarbital
L-Ascorbic acid	Hydrocortisone	Phentermine
DL-Amphetamine sulfate	O-Hydroxyhippuric acid	Trans-2-phenylcyclopropylamine hydrochloride
Apomorphine	p-Hydroxyamphetamine	
Aspartame	p-Hydroxy-methamphetamine	L-Phenylephrine
Atropine	3-Hydroxytyramine	β-Phenylethylamine
Benzilic acid		Phenylpropanolamine
Benzoic acid	Ibuprofen	Prednisolone
Benzoylcegonine	Imipramine	Prednisone
Benzphetamine	Iproniazid	Procaine
Bilirubin	(±) - Isoproterenol	Promazine
(±)	-Isoxsuprine	Promethazine
Brompheniramine		
Caffeine	Ketamine	DL-Propranolol
Cannabidiol	Ketoprofen	D-Propoxyphene
Cannabinol	Labetalol	D-Pseudoephedrine
Chloralhydrate	Levorphanol	Quinacrine

Chloramphenicol	Loperamide	Quinidine	ATLAS MEDICAL Unit 4, William James House Cowley Rd, Cambridge, CB4 0WX Tel: ++44 (0) 1223 858 910 Fax: ++44 (0) 1223 858 524
Chlorothiazide	Mephentermine	Quinine	
(±)	-Maprotiline	Ranitidine	
Chlorpheniramine			
Chlorpromazine	Meperidine	Salicylic acid	
Chlorquine	Meprobamate	Secobarbital	
Cholesterol	Methamphetamine	Serotonin	
Clomipramine	Methoxyphenamine	Sulfamethazine	
Clonidine	(±) - 3,4-	Sulindac	
Cocaethylene	Methylenedioxy- amphetamine hydrochloride	Temazepam	PPI434A01
Cocaine	(±) - 3,4-	Tetracycline	Revision A (12.03.2007)
hydrochloride	Methylenedioxy-meth- amphetamine hydrochloride	Tetrahydrocortisone , 3-acetate	
Codeine	Morphine-3-β-D glucuronide	Tetrahydrocortisone 3- (β-D-glucuronide)	
Cortisone	Morphine Sulfate	Tetrahydrozoline	
(-) Cotinine			
Creatinine			
Deoxycorticosterone	Nalidixic acid		
Dextromethorphan	Naloxone	Thebaine	
Diazepam	Naltrexone	Thiamine	
Diclofenac	Naproxen	Thioridazine	
Diflunisal	Niacinamide	DL-Tyrosine	
Digoxin	Nifedipine	Tolbutamide	
Diphenhydramine	Norcodein	Triamterene	
EDDP	Norethindrone	Trifluoperazine	
EMDP	D-Norpropoxyphene	Trimethoprim	
Ecgonine	Noscapine	Trimipramine	
hydrochloride			
Ecgonine	DL-Octopamine	Tryptamine	
methylester			
(-) -Ψ -Ephedrine	Oxalic acid	DL-Tryptophan	
[1R,2S]	(-)Oxazepam	Tyramine	
Ephedrine			
(L) - Epinephrine	Oxolinic acid	Uric acid	
Erythromycin	Oxycodone	Verapamil	
β-Estradiol		Zomepirac	

BIBLIOGRAPHY

1. Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991; 216
2. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
3. Hawks RL, CN Chiang. *Urine Testing for Drugs of Abuse*. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986